Contact

HEOR Evidence Generation.

Demonstrate the value of your therapies.

See our full suite of Value, Pricing & Access services

What we do.

Demonstrate value through proven analytical methods and lead the discussion for valuing new innovations.

Our team of health economists and HEOR strategists apply deep HTA experience to inform your reimbursement strategy, guide you through HTA processes, and support your value communications strategies beyond product launch.

How we help.

Leverage proven analytical methods for HEOR evidence generation with our commercial experience and scientific expertise. Our economic modelling and HTA specialists can inform pricing strategy, identify priorities for evidence generation, and develop global models that meet the latest HTA requirements, including for local submissions.

Beyond that, we maintain a team of highly qualified Patient Reported Outcomes (PRO) specialists who generate and analyze health-related utility data to strengthen your product’s value proposition.

Learn about our Centers of Excellence

Our HEOR strategies include:

Early economic and budget impact models
Patient-Reported Outcome (PRO) solutions
Burden of illness and patient preference studies
Evidence generation strategies for HTA submissions

Featured case study

HTA evidence generation & preparedness for a novel oncology treatment.

Our team of experts provided full service HTA support to our client to achieve success in HTA submissions and pricing negotiations across Europe for an innovative oncology treatment.

View all case studies

HTA evidence generation and preparedness for a novel oncology treatment

Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment.

Get to know some of our experts.

Jasmine Farrington

Catriona Crossan

Principal, Head of Health Economic Modelling, HEOR

Yemi Oluboyede

Principal, Health Economics and Outcomes Research

Latest thinking.

Get the latest insights and perspectives from our experts.

View all of our resources

HTA evidence generation and preparedness for a novel oncology treatment

Our client needed successful HTA evidence packages and submissions to achieve reimbursement across Europe for an innovative oncology treatment.

Webinar on the IRA in partnership with BioCentury

Scott Briggs, Principal, joined a live panel of industry experts to discuss the Inflation Reduction Act on March 30th.

Indirect treatment comparison (ITC) to generate comparative effectiveness evidence

A company was approaching the European market with evidence from a placebo-controlled RCT, but with several established competitors.

Early value insights to drive value definition and evidence need to produce TrPP

The client wanted to understand the key drivers of value for the new treatment for sleep disorders including narcolepsy.

Get in touch.

Looking to get in touch with an expert or team member?

Tell us how we can help.

Contact us today

Related offerings.

Value, Pricing & Access

Learn more

Evidence Synthesis & RWE Generation

Learn more

Value, Pricing & Access Strategy

Learn more

View all of our areas of expertise